Monthly News Roundup - January 2020

Trijardy XR: A Triple Drug Combo Approved for Type 2 Diabetes In January, the US Food and Drug Administration (FDA) approved once-daily Trijardy XR (empagliflozin, linagliptin, and metformin hydrochloride extended release tablets) to lower blood...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news

Related Links:

Conclusions: In the current study, the prevalence of depression among diabetic outpatients was higher than that of studies conducted in other settings. Depression was significantly associated with female sex, rural residency, type 2 diabetes mellitus, duration of illness> 6 years, high fear of complications, and poor social support. PMID: 32243106 [PubMed - as supplied by publisher]
Source: The Primary Care Companion for CNS Disorders - Category: Primary Care Tags: Prim Care Companion CNS Disord Source Type: research
This study was an open-label, parallel controlled study. Patients were included if they were newly diagnosed with type 2 diabetes (
Source: Medical Science Monitor - Category: Research Tags: Med Sci Monit Source Type: research
CONCLUSIONS In this study, we screened 104 lncRNA therapeutic targets and several signaling pathways (Wnt, PPAR, amino acid metabolism signaling pathway, mTOR, and lipid metabolism-related pathways) of liraglutide against T2DM based on lncRNA sequencing. PMID: 32238798 [PubMed - in process]
Source: Medical Science Monitor - Category: Research Tags: Med Sci Monit Source Type: research
CONCLUSIONS A prognostic model based on six variables was predictive for incident type 2 diabetes mellitus and prediabetes in a healthy population in Japan. PMID: 32235819 [PubMed - in process]
Source: Medical Science Monitor - Category: Research Tags: Med Sci Monit Source Type: research
Anti‑glycolipid disorder effect of epigallocatechin‑3‑gallate on high‑fat diet and STZ‑induced T2DM in mice. Mol Med Rep. 2020 Mar 26;: Authors: Ren Z, Yang Z, Lu Y, Zhang R, Yang H Abstract Epigallocatechin-3-gallate (EGCG) is beneficial for inhibiting dyslipidemia and reducing hyperlipidemic risk. The purpose of the present study was to investigate the glycolipid regulatory effects and potential mechanisms of EGCG in a high‑fat diet and streptozotocin‑induced type 2 diabetes mellitus (T2DM) mouse model. The results demonstrated that EGCG can decrease blood glucose levels and i...
Source: Molecular Medicine Reports - Category: Molecular Biology Tags: Mol Med Rep Source Type: research
Authors: Huang YM, Shiyanbola OO, Chan HY, Smith PD Abstract Background: Type 2 diabetes (T2D) incurs tremendous health cost associated with various complications due to poor diabetes control. Medication adherence, which is correlated with patients' health literacy, should be consistently practiced achieving optimal diabetes control. A deeper understanding of the specific communication and psychosocial factors related to medication-taking behaviors across different levels of health literacy among people with T2D will guide the development of effective interventions and strategies to enhance medication adherence.Obj...
Source: Postgraduate Medicine - Category: Internal Medicine Tags: Postgrad Med Source Type: research
AbstractBackgroundRandomized controlled clinical trials (RCT) have demonstrated varied efficacy of glucagon-like peptide-1 receptor (GLP-1R) agonists for cardiovascular outcomes. We sought to evaluate the efficacy and safety of GLP-1R agonists among patients with Type 2 diabetes mellitus (DM) for stroke prevention.MethodsWe conducted a systematic review and meta-analysis of RCTs reporting the following outcomes among patients with Type 2 DM treated with GLP-1R agonists (vs. placebo): nonfatal or fatal strokes, all-cause or cardiovascular mortality, myocardial infarction (MI) and major adverse cardiovascular events (MACE). ...
Source: Journal of Neurology - Category: Neurology Source Type: research
ConclusionsParticipants with T2D showed an accelerated decline in muscle mass compared to non-diabetic participants. Insulin therapy was associated with preserved muscle mass, but not muscle function parameters, indicating a discrepancy between muscle mass and function in this high-risk population.
Source: Acta Diabetologica - Category: Endocrinology Source Type: research
oshima Michiaki Fukui Thrombopoietin (THPO) is a circulatory cytokine that plays an important role in platelet production. The presence of anti-THPO antibody relates to thrombocytopenia and is rarely seen in hematopoietic and autoimmune diseases. To date, there had been no reports that focused on the anti-THPO antibody in patients with type 2 diabetes mellitus (T2DM). To evaluate prevalence of the anti-THPO antibody in patients with T2DM and the relationship between anti-THPO antibody and platelet count, a cross-sectional study was performed on 82 patients with T2DM. The anti-THPO antibody was measured by ELISA using...
Source: Molecules - Category: Chemistry Authors: Tags: Article Source Type: research
Ignoring a problem won ’t make it go away. I say this all the time, with love and compassion, to my patients who are having trouble accepting a diagnosis. Ignoring your Type 2 Diabetes, for example, won’t make it any less real. It will only land you in renal failure and on dialysis, or with a […]Find jobs at  Careers by KevinMD.com.  Search thousands of physician, PA, NP, and CRNA jobs now.  Learn more.
Source: Kevin, M.D. - Medical Weblog - Category: General Medicine Authors: Tags: Conditions COVID-19 coronavirus Infectious Disease Source Type: blogs
More News: Diabetes | Diabetes Type 2 | Empagliflozin | Endocrinology | Food and Drug Administration (FDA) | Fortamet | Jardiance | Metformin | Pharmaceuticals